179 related articles for article (PubMed ID: 37446098)
1. Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients.
Mauro M; Ugo P; Walton Z; Ali S; Rastellini C; Cicalese L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446098
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
Wang L; Yao M; Pan LH; Qian Q; Yao DF
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
[TBL] [Abstract][Full Text] [Related]
3. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
4. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
[TBL] [Abstract][Full Text] [Related]
5. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review).
Montalbano M; Georgiadis J; Masterson AL; McGuire JT; Prajapati J; Shirafkan A; Rastellini C; Cicalese L
Oncol Rep; 2017 Mar; 37(3):1291-1300. PubMed ID: 28098909
[TBL] [Abstract][Full Text] [Related]
6. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma.
Yao M; Wang L; Fang M; Zheng W; Dong Z; Yao D
Biosci Trends; 2016 Nov; 10(5):337-343. PubMed ID: 27795482
[TBL] [Abstract][Full Text] [Related]
7. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
8. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.
Wang L; Pan L; Yao M; Cai Y; Dong Z; Yao D
Oncotarget; 2016 Jul; 7(27):42150-42158. PubMed ID: 27286460
[TBL] [Abstract][Full Text] [Related]
9. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
[TBL] [Abstract][Full Text] [Related]
10. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
Wang JY; Wang XK; Zhu GZ; Zhou X; Yao J; Ma XP; Wang B; Peng T
BMC Cancer; 2021 Apr; 21(1):462. PubMed ID: 33902495
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
14. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
15. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.
Dong Z; Yao M; Wang L; Yang J; Yao D
Mini Rev Med Chem; 2014; 14(14):1183-93. PubMed ID: 25553423
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.
Cui X; Li Z; Gao PJ; Gao J; Zhu JY
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):157-63. PubMed ID: 25865688
[TBL] [Abstract][Full Text] [Related]
17. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.
Allegretta M; Filmus J
Anticancer Agents Med Chem; 2011 Jul; 11(6):543-8. PubMed ID: 21554204
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
20. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
